Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76���K trial.
John M Kirkwood, Peter Mohr, Christoph Hoeller, Jean-Jacques Grob, Michele Del Vecchio, Jennifer Lord-Bessen, Swetha Srinivasan, Ayman Nassar, Federico Campigotto, Hannah Fairbanks, Fiona Taylor, Rachael Lawrance, Georgina V Long, Jeffrey Weber
Author Information
John M Kirkwood: UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: kirkwoodjm@upmc.edu.
Peter Mohr: Elbe-Kliniken Buxtehude, Buxtehude, Germany.
Christoph Hoeller: Medical University of Vienna, Vienna, Austria.
Jean-Jacques Grob: Aix-Marseille University, H��pital de la Timone, Marseille, France.
Michele Del Vecchio: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Jennifer Lord-Bessen: Bristol Myers Squibb, Princeton, NJ, USA.
Swetha Srinivasan: Bristol Myers Squibb, Princeton, NJ, USA.
Ayman Nassar: Bristol Myers Squibb, London, UK.
Federico Campigotto: Bristol Myers Squibb, Princeton, NJ, USA.
BACKGROUND: In the phase 3 CheckMate 76���K trial, adjuvant nivolumab significantly improved recurrence-free survival and distant metastasis-free survival versus placebo in patients with resected stage IIB/C melanoma. We report patient-reported outcomes from CheckMate 76���K. METHODS: Change from baseline to week 53 in health-related quality of life (HRQoL), as measured using the EORTC QLQ-C30 and EQ-5D-5L utility index and visual analog scale (VAS), was compared between treatment groups using linear mixed-effect models. Time to confirmed deterioration (TTCD) in HRQoL was assessed using Cox regression. Bother from side effects, as measured by the FACIT-GP5, was descriptively compared between treatment groups. RESULTS: There were no clinically meaningful differences in change from baseline between treatment groups in EORTC QLQ-C30 subscales, including global health status (GHS)/quality of life (QoL; least squares mean [LSM] difference: -1.3; 95���% confidence interval [CI]: -2.9, 0.4), and EQ-5D-5L utility index (LSM difference: -0.011; 95���% CI: -0.025, 0.004) and VAS (LSM difference: -1.3; 95���% CI: -2.6, 0.0). There was no difference in TTCD for nivolumab versus placebo in EORTC QLQ-C30 GHS/QoL (hazard ratio [HR]: 1.10; 95���% CI: 0.88, 1.36) or EQ-5D-5L utility index (HR: 1.10; 95���% CI: 0.86, 1.42); however, TTCD in EQ-5D-5L VAS was longer with placebo (HR: 1.92; 95���% CI: 1.39, 2.64). Proportions of patients reporting severe side effect bother ("quite a bit"/"very much") were minimal (nivolumab: 1���%-4���%; placebo: 0���%-2���%). CONCLUSIONS: Patients with resected stage IIB/C melanoma treated with adjuvant nivolumab demonstrated stable HRQoL and minimal bother from side effects. CLINICAL TRIAL INFORMATION: NCT04099251.
